Maze Therapeutics, Inc.
MAZE Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2024–FY2025
Last close · Oct 23, 2026
$31.01
2.9%What Maze Therapeutics, Inc. does
No business description yet.
- Legal name
- Maze Therapeutics, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Accession · CIK
- 0001193125-26-122778
0001842295
Revenue and margins
Maze Therapeutics, Inc. had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$113M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Maze Therapeutics, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 1,474.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably Maze Therapeutics, Inc. can carry it.
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $197M | $342M |
| Current ratio | 9.8x | 15.5x |
| Quick ratio | 9.8x | 15.5x |
| Total assets | $241M | $397M |
| Total liabilities | $43.6M | $42.2M |
| Shareholders' equity | −$311M | $355M |
| Net debt (− = net cash) | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | ✓ | ✕ |
| Cash from operations is positive | ✓ | ✕ |
| Return on assets rose | — | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | ✓ |
| Share count didn't rise | — | ✕ |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | — |
| F-score | — / 3 | — / 6 |
| Accruals ratio | −9.9% | −6.0% |
| Altman Z'' | −5.80 | 7.81 |
2 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | $168M | — |
| Research and development | $83.5M | $108M |
| Operating income | $57.6M | −$143M |
| Pretax income | $53.4M | −$131M |
| Income tax | $1.2M | $0.0M |
| Net income | $52.2M | −$131M |
| Net income to common | $3.4M | −$131M |
| Diluted EPS | $1.25 | −$3.05 |
| Diluted shares | 0.00B | 0.04B |
| Cash flow | ||
| Cash from operations | $76.0M | −$112M |
| Capital expenditure | $1.1M | $0.8M |
| Free cash flow | $74.8M | −$113M |
| Depreciation and amortization | $3.3M | $2.4M |
| Stock-based compensation | $9.6M | $16.4M |
| Balance sheet | ||
| Cash and short-term investments | $197M | $342M |
| Current assets | $202M | $350M |
| Current liabilities | $20.7M | $22.6M |
| Property and equipment, net | $6.7M | $5.0M |
| Total assets | $241M | $397M |
| Total liabilities | $43.6M | $42.2M |
| Preferred stock | $0.0M | $0.0M |
| Shareholders' equity | −$311M | $355M |
| Margins | ||
| Operating margin | 34.4% | — |
| EBITDA margin | 36.3% | — |
| Net margin | 31.2% | — |
| FCF margin | 44.7% | — |
| Returns | ||
| Return on capital employed | 26.2% | −38.2% |
| Return on equity | — | −599.0% |
| Return on assets | 21.7% | −41.1% |
| Return on tangible equity | — | −36.9% |
| Growth | ||
| Net income growth | — | −351.0% |
| EPS growth | — | −344.0% |
| FCF growth | — | −250.7% |
| Share count change | — | 1,474.0% |
| Financial health | ||
| Current ratio | 9.8x | 15.5x |
| Quick ratio | 9.8x | 15.5x |
| Capital allocation | ||
| Capex / revenue | 0.7% | — |
| Stock comp / revenue | 5.8% | — |
| Quality scores | ||
| Altman Z'' | −5.8 | 7.8 |
| Accruals ratio | −9.9% | −6.0% |
Source: SEC EDGAR XBRL filings (CIK 0001842295). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.